Isopto Carpine (Pilocarpine Hydrochloride)

• Isopto Carpine, a miotic ophthalmic agent, is used to manage conditions that require reduction of intra‑ocular pressure or pupil constriction.
• Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
• Acute angle‑closure glaucoma: promotes miosis to open the angle and improve aqueous outflow.
• Diagnostic procedures requiring miosis: induces pupil constriction to enhance visualization during eye examinations.

• Pilocarpine hydrochloride acts as a direct agonist at muscarinic (M3) receptors in the eye. Stimulation of these receptors contracts the sphincter pupillae muscle, producing miosis, and contracts the ciliary muscle, which opens the trabecular meshwork, enhancing aqueous humor outflow and thereby lowering intra‑ocular pressure. The increased outflow reduces fluid volume within the anterior chamber, providing therapeutic control of pressure.

Pilocarpine ophthalmic solution may cause ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects

• Blurred vision
• Eye irritation or burning sensation
• Redness of the conjunctiva
• Increased tearing

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, angioedema)
• Persistent myopia or worsening of near vision
• Corneal ulceration or keratitis

• When prescribing Isopto Carpine, clinicians should observe several safety considerations to minimize risk.
• Monitor intra‑ocular pressure: assess response after initiation.
• Use with caution in patients with asthma or chronic obstructive pulmonary disease: cholinergic stimulation may affect bronchial tone.
• Avoid in narrow‑angle glaucoma unless specifically indicated: may precipitate angle closure.
• Caution when combined with anticholinergic medications: may reduce therapeutic effect.
• Store at room temperature: keep in the original container, protect from light and moisture.

Pilocarpine can interact with other agents that influence cholinergic pathways or ocular physiology.

Major Interactions (Avoid)

• Anticholinergic drugs (e.g., atropine, scopolamine): may antagonize pilocarpine’s miotic effect.
• Systemic cholinesterase inhibitors (e.g., donepezil, rivastigmine): risk of excessive cholinergic stimulation.
• Beta‑blocker ophthalmic solutions used concurrently: additive intra‑ocular pressure reduction may lead to hypotony.

Moderate Interactions (Monitor Closely)

• Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase ocular irritation.
• Systemic antihistamines: may diminish miotic response.
• Cycloplegic agents (e.g., tropicamide): may oppose pupil constriction.